Thursday, 7 July 2022
  
Login

Australia's most trusted
source of pharma news

Thursday, 07 July 2022
Listen to this story 
News

Aussie's US cancer milestone

Posted 20 May 2022 AM

Imugene has finally moved its novel cancer-killing virus therapy Vaxinia into clinical trials and has high hopes it can make MSD's PD-1 inhibitor Keytruda more effective in solid tumours.

The Sydney-based company acquired global exclusive license rights to the oncolytic virus technology developed by researchers at City of Hope, a world-renowned cancer research and treatment organisation in Los Angeles back in 2019.

To see the whole article, please login

Popular

Global bosses shunning Aust
AZ cuts jobs in sales make over
Pay envy driving up resignations
Who's getting promoted?
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (7)

Sales & Customer Relations (26)

Access & Reimbursement (2)

Clinical & Medical, R&D (14)

Regulatory, Pharmacovigilance & QA (8)

Devices (1)

Other (29)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2022 Lush Media | Privacy Statement | Subscribe to Pharma in Focus